Translational Imaging Research Program in Radiopharmaceutical Sciences

项目摘要。 华盛顿大学T32博士后培训基金“翻译成像” 放射性药物科学“(简称”TIRS“)是一项多学科倡议，旨在培训 下一代PET分子成像科学家将设计、开发和翻译PET 放射性示踪剂在非侵入性病理生理检测中的作用 神经退行性疾病和ADRDS。该培训计划将由以下人员带头 Mallinckrodt放射研究所(MIR)，一所世界闻名的 转译PET研究，是放射性药物科学家的首选第一站 学习应用核成像研究。为了实现这一新的培训目标，T32 TIR计划汇集了和平号放射科学部的顶尖科学家，骑士 阿尔茨海默病研究中心(Knight ADRC)，分子成像中心，研究所 临床和翻译科学，回旋加速器-GMP设备和PET-放射性示踪剂翻译 和资源中心(通过NIBIB的P41课程)和教职员工作为12岁以下的导师 部门须达致为调查新的或现有的调查而拟进行的训练目标 介导AD和ADRD的生物标记物具有重叠的病理生理学，有助于非侵入性 及早发现疾病，促进药物开发，并允许分层治疗 管理病人护理的范例。值得注意的是，T32轮胎的导师包括化学家， 生物化学家、生物医学工程师、免疫学家、神经学家、精神病学家、放射化学家， 还有放射科医生。博士后实习生将通过各种参与方式抽签 医学院和丹福斯校区的系，包括 圣路易斯大都会地区和附近的中西部学术机构。我们正在提议 每年培养3名博士后实习生，每名实习生为期2年 培训，超过5年的T32计划。所有受训人员将通过双重机制进行培训- 导师制(在基础科学和其他医生-科学家之间提供多学科指导) 培训)，所有受训人员都将接受负责任的研究行为培训，包括指导 以实验严谨的方法实现可重现的科学。值得注意的是，科学家们 在神经科学和放射性药物科学的交界处的培训也很迅速。 在全国范围内普遍下降，放射性药物科学家明显短缺 在美国劳动力中的所有人都是如此。因此，我们的T32博士后培养计划 预计将大大满足放射性药物科学家的严重短缺 在神经科学和放射性药物科学的交汇点上接受培训。虽然我们目前 T32 TIR计划任务是针对ADRD的学员的，我们设想培训 分子PET成像研究人员也可以服务于其他部门和领域 因此，包括内科肿瘤学在内，扩大了TIR培训的意义和范围 项目--远远超出神经科学领域。总体而言，我们(T32 TRS计划总监和 联席主任)相信，通过该计划培养的博士后科学家将 在全国范围内过渡到教员职位，预计将服务于诊断领域 核医学在神经科学领域已经有几十年的历史了。

Project Summary. The Washington University T32 postdoctoral training grant “Translational Imaging in Radiopharmaceutical Sciences” (abbreviated as “TIRS”) is a multidisciplinary initiative to train the next generation of PET molecular imaging scientists to design, develop, and translate PET radiotracers for noninvasive detection of pathophysiology mediating development of neurodegenerative diseases and ADRDs. This training program will be spearheaded by Mallinckrodt Institute of Radiology (MIR), an institution known worldwide as a frontier for translational PET research, and a preferred first stop for radiopharmaceutical scientists for learning applied nuclear imaging research. To accomplish this novel training objective, the T32 TIRS program brings leading scientists from radiological sciences division of the MIR, the Knight Alzheimer’s Disease Research Center (Knight ADRC), Molecular Imaging Center, Institute of Clinical and Translational Sciences, Cyclotron-GMP facility and PET-Radiotracer Translational and Resource Center (P41 program through NIBIB) and faculty members as mentors from 12 departments to accomplish aims of proposed training for investigation of new or existing biomarkers mediating AD and ADRDs with overlapping pathophysiology, assist in noninvasive early detection of diseases, facilitating drug development and allow stratification of treatment paradigms for managing patient care. Of note, the T32 TIRS mentors include chemists, biochemists, biomedical engineers, immunologists, neurologists, psychiatrists, radiochemists, and radiologists. The postdoctoral trainees will be drawn through various participating departments at the medical school, and Danforth campus, including other universities in metropolitan St. Louis area, and nearby academic institutions in the Midwest. We are proposing to train 3 postdoctoral trainees each year, wherein each trainee will be enrolled for 2 years of training, over 5 years of the T32 program. All trainees will be trained through mechanism of dual- mentorship (one in basic science and other physician-scientist to provide multidisciplinary training) and all trainees will be trained in responsible conduct of research including instructions in methods of experimental rigor for accomplishing reproducible science. Of note, scientists training at the interface of neuroscience and radiopharmaceutical sciences are also rapidly declining nationwide in general, and there is a clear shortage of radiopharmaceutical scientists across the board in the US workforce. Therefore, our T32 postdoctoral training program TIRS would be expectedly to substantially meet this critical shortage of radiopharmaceutical scientists trained at the interface of neuroscience and radiopharmaceutical sciences. Although our current T32 TIRS programmatic mission is directed for trainees at ADRDs, we envision that trained molecular PET imaging research scientists could also serve other departments and fields including the medical oncology, therefore, extending significance and scope of TIRS training program well-beyond the field of neuroscience. Overall, we (the T32 TIRS program director and co-directors) are confident that postdoctoral scientists trained through this program will be transitioning into faculty positions nationwide and will be expected to serve the field of diagnostic nuclear medicine in neuroscience for several decades.